[1]王力伟,周晓洲,陈志文,等.膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究[J].第三军医大学学报,2018,40(08):711-716.
 WANG Liwei,ZHOU Xiaozhou,CHEN Zhiwen,et al.Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer[J].J Third Mil Med Univ,2018,40(08):711-716.
点击复制

膀胱癌循环肿瘤细胞NANOG基因的表达与临床特征相关性的初步研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第08期
页码:
711-716
栏目:
临床医学
出版日期:
2018-04-30

文章信息/Info

Title:
Correlation of Nanog expression in circulating tumor cells with clinical characteristics of patients with bladder cancer
作者:
王力伟周晓洲陈志文杨劲
陆军军医大学(第三军医大学):第一附属医院全军泌尿外科研究所1,基础医学院细胞生物教研室
Author(s):
WANG Liwei ZHOU Xiaozhou CHEN Zhiwen YANG Jin

Institute of Urology, First Affiliated Hospital, 2Department of Cell Biology, College of Basic Medical Sciences, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
膀胱癌循环肿瘤细胞Nanog上皮间质转化转移
Keywords:
bladder cancer circulating tumor cells Nanog epithelial-mesenchymal transition metastasis
分类号:
R181.32;R730.43;R737.14
文献标志码:
A
摘要:

目的    探讨膀胱癌患者外周血循环肿瘤细胞(circulating tumor cells,CTCs)及其中Nanog基因的阳性表达率与临床特征的相关性。  方法    选取2015年12月至2016年8月陆军军医大学第一附属医院全军泌尿外科研究所收治的膀胱尿路上皮癌患者59例,采用广州益善生物技术股份有限公司开发的CanpatrolTM技术检测患者外周血中的CTCs分布情况及CTCs中Nanog基因的表达水平,分析上述检测结果与患者性别、年龄、肿瘤分级、浸润程度、淋巴结活检以及转移情况之间的相关性。结果    肌层浸润性膀胱癌患者外周血中CTCs阳性率高于非肌层浸润性膀胱癌患者(33/36,91.7% vs 14/23,60.9%,P=0.007);淋巴结活检阳性膀胱癌患者CTCs阳性率高于淋巴结活检阴性患者(19/20,95.0% vs 28/39,71.8%,P=0.044);混合型CTCs中Nanog基因的阳性率高于上皮型(22/56,39.3% vs 96/176,54.5%,P=0.047)。结论    CTCs可作为判断膀胱癌恶性程度和侵袭能力的辅助指标,CTCs中的Nanog基因有望成为评估膀胱癌转移和预后的生物标志。

Abstract:

Objective    To investigate the correlation between Nanog expression in circulating tumor cells (CTCs) and the clinical features of patients with bladder cancer.  Methods    CTCs were isolated from 59 patients with bladder urothelial carcinoma and classified into epithelial, mesenchymal and bi-phenotypic CTCs. Nanog expression in the CTCs was detected using CanpatrolTM technique. The positivity of CTCs and Nanog positivity in the CTCs were analyzed in these patients in relation with the patients' clinical features.  Results    The positivity rate of CTCs was significantly higher in patients with muscle invasive bladder cancer (MIBC) than in those with non-muscle invasive bladder cancer (NMIBC) [41/44 (93.2%) vs 6/15 (40.0%), P=0.007], and was also significantly higher in the patients with positive biopsy findings of the lymph nodes than in those with negative findings [19/20 (95.0%) vs 28/39 (71.8%), P=0.044]. Bi-phenotypic CTCs were found to have a higher rate of Nanog positivity than epithelial CTCs [22/56 (39.3%) vs 96/176 (54.5%), P=0.047].  Conclusion    CTCs positivity can assist in the evaluation of malignancy and invasiveness of bladder cancer, and Nanog expression in the CTCs has the potential to serve as a biomarker for evaluating metastasis and prognosis of bladder cancer.
 

参考文献/References:

[1]PARKINSON D R, DRACOPOLI N, PETTY B G, et al. Considerations in the development of circulating tumor cell technology for clinical use[J]. J Transl Med, 2012, 10: 138-157. DOI: 10.1186/1479-5876-10138.
[2]CARVALHO F L, SIMONS B W, ANTONARAKIS E S, et al. Tumorigenic potential of circulating prostate tumor cells[J]. Oncotarget, 2013, 4(3): 413-421. DOI:  10.18632/oncotarget.895.
[3]NGUYEN L V, VANNER R, DIRKS P, et al. EAVES CJ(2012) Cancer stem cells:  an evolving concept[J]. Nat Rev Cancer, 2012, 12(2): 133-143. DOI:  10.1038/nrc3184.
[4]MITSUI K, TOKUZAWA Y, ITOH H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells[J]. CELL, 2003, 113(5): 631-642. DOI:  10.1016/S00928674(03)00393-3.
[5]WU S, LIU S, LIU Z, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers[J]. PLoS One,2015,10(4): e0123976. DOI:  10.1371/journal.pone.0123976.
[6]GAWLIKRZEMIENIEWSKA N, BEDNAREK I. The role of Nanog transcriptional factor in the development of malignant phenotype of cancer cells[J]. Cancer Biol Ther, 2016, 17(1): 1-10. DOI:  10.1080/15384047.2015.1121348.
[7]FRIEDLANDER T W, PREMASEKHARAN G, PARIS P L. Looking back, to the future of circulating tumor cells[J]. Pharmacol Ther, 2014, 142(3): 271-280. DOI: /10.1016/j.pharmthera.2013.12.011.
[8]ACETO N, BARDIA A, MIYAMOTO D T, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis[J]. Cell, 2014, 158(5):  1110-1122. DOI:  10.1016/j.cell.2014.07.013.
[9]KNIGSBERG R, OBERMAYR E, BISES G, et al. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients[J]. Acta Oncol, 2011, 50(5): 700-710. DOI:  10.3109/0284186X.2010.549151.
[10]WU S, LIU Z, LIU S, et al.Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions[J]. Clin Chem Lab Med, 2013, 9: 1-9. DOI:  10.1515/cclm20130558.
[11]AIELLO N M, BRABLETZ T, KANG Y, et al. Upholding a role for EMT in pancreatic cancer metastasis[J]. Nature, 2017, 547(7661):  E7-E8. DOI:  10.1038/nature22963.
[12]TURKER I, UYETURK U, SONMEZ O U, et al. Detection of circulating tumor cells in breast cancer patients:  prognostic predictive role[J]. Asian Pac J Cancer Prev, 2013, 14(3): 1601-1607. DOI:  10.7314/APJCP.2013.14.3.1601.
[13]BORK U, RAHBARI N N, SCHOLCH S, et al.Circulating tumour cells and outcome in non-metastatic colorectal cancer:  a prospective study[J]. Br J Cancer, 2015, 112(8): 1306-1313. DOI:  10.1038/bjc.2015.88.
[14]THALGOTT M, RACK B, HORN T, et al. Detection of circulating tumor cells in locally advanced highrisk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy[J]. Anticancer Res, 2015, 35(10): 5679-5685.
[15]CHOU R, GORE J L, BUCKLEY D, et al. Urinary biomarkers for diagnosis of bladder cancer:  a systematic review and metaanalysis[J]. Ann Intern Med,2015,163(12): 922-931. DOI:  10.7326/m150997. DOI: 10.7326/M150997.
[16]MICALIZZI D S, MAHESWARAN S, HABER D A. A conduit to metastasis:  circulating tumor cell biology[J]. Genes Dev,2017,31(18): 1827-1840. DOI:  10.1101/gad.305805.117.
[17]BEDNARZKNOLL N, ALIXPANABI6RES C, PANTEL K. Plasticity of disseminating cancer cells in patients with epithelial malignancies [J]. Cancer Metastasis Rev, 2012, 31(3-4): 673-687. DOI 10.1007/s10555-012-9370-z.
[18]RINK M1,SOAVE A, ENGEL O, et al. Tumor cells in the peripheral blood of patients with urothelial carcinoma of the bladder:  detection and impact of circulating[J]. Urologe A, 2014, 53(4): 501-508. DOI: 10.1007/s00120-014-3443-2.
[19]KREGEL S, SZMULEWITZ R Z, VANDER GRIEND D J. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells [J]. Prostate, 2014, 74(15):  1530-1543. DOI: 10.1002/pros.22870.
[20]LIU C W, LI C H, PENG Y J, et al. Snail regulates Nanog status during the epithelialmesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in nonsmallcell lung cancer[J]. Oncotarget,2014, 5(11): 3880-3894. DOI:  10.18632/oncotarget.2006.
[21]王志, 张艺, 黄亚琴, 等. 干性基因Nanog在膀胱癌组织中的表达及其对膀胱癌细胞增殖与耐药的作用[J]. 第三军医大学学报, 2014, 36(7): 655-658. DOI: 10.16016/j.10005404.2014.07.023.
WANG Z, ZHANG Y, HUANG Y Q, et al. Expression of Nanog in bladder cancer and its role in proliferation and drug resistance of bladder cancer cells[J]. J Third Mil Med Univ, 2014, 36(7): 655-658.DOI: 10.16016/j.1000-5404.2014.07.023

相似文献/References:

[1]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[2]齐晓伟,姜军,杨新华,等.乳腺癌循环肿瘤细胞与原发肿瘤临床病理特征关系的初步研究[J].第三军医大学学报,2009,31(09):850.
 QI Xiao-wei,JIANG Jun,YANG Xin-hua,et al.Circulating tumor cells and clinicopathologic characteristics of primary tumor of breast cancer patients: report of 128 cases[J].J Third Mil Med Univ,2009,31(08):850.
[3]李雪涛,陈芳琳,王欣欣,等.95D细胞转移相关基因在原发灶、循环肿瘤细胞和转移灶中的差异表达[J].第三军医大学学报,2011,33(10):980.
 Li Xuetao,Chen Fanglin,Wang Xinxin,et al.Differential expression of metastasis-associated genes in primary tumor, circulating tumor cells, and metastasis of human giant-cell lung cancer cell line 95D[J].J Third Mil Med Univ,2011,33(08):980.
[4]李世超,姜军,杨新华,等.乳腺癌分子分型与外周血循环肿瘤细胞相关性探讨[J].第三军医大学学报,2012,34(10):1006.
 Li Shichao,Jiang Jun,Yang Xinhua,et al.Correlation between molecular subtypes and circulating tumor cells in breast cancer[J].J Third Mil Med Univ,2012,34(08):1006.
[5]王明浩,杨新华,张毅,等.乳腺癌外周血循环肿瘤细胞变化与新辅助化疗效果的关系[J].第三军医大学学报,2013,35(11):1148.
 Wang Minghao,Yang Xinhua,Zhang Yi,et al.Relationship of peripheral blood circulating tumor cells with therapeutic effect of neoadjuvant chemotherapy in breast cancer: report of 70 cases[J].J Third Mil Med Univ,2013,35(08):1148.
[6]刘鑫,王一星,李冠宏,等.Cytokeratin和CD133在肺腺癌患者外周血中的联合检测及临床病理分析[J].第三军医大学学报,2017,39(20):2004.
 LIU Xin,WANG Yixing,LI Guanhong,et al.Combined detection and clinical pathological analysis of peripheral blood CK and CD133 in primary lung adenocarcinoma patients[J].J Third Mil Med Univ,2017,39(08):2004.

更新日期/Last Update: 2018-04-28